• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE; PULMONARY VALVE PROSTHESIS PERCUTANEOUSLY DELIVERED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE; PULMONARY VALVE PROSTHESIS PERCUTANEOUSLY DELIVERED Back to Search Results
Model Number 9600TFX26
Device Problem Positioning Problem (3009)
Patient Problem Pulmonary Regurgitation (2023)
Event Date 09/22/2020
Event Type  Injury  
Manufacturer Narrative
Per the pulmonic ifu, the edwards commander delivery system and accessories are indicated for use as an adjunct to surgery in the management of pediatric and adult patients with the following clinical conditions: dysfunctional rvot conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention, and: regurgitation: = moderate regurgitation, and/or stenosis: mean rvot gradient = 35 mmhg.Per the instructions for use (ifu), valve malposition is a known potential complication associated with the use of the transcatheter heart valve (thv).There are multiple patient and procedural factors that alone or in combination can cause or contribute to valve malposition, including, but not limited to, incorrect sizing of the landing area, improper positioning prior to deployment, poor image intensifier angle, poor coaxial alignment of the valve/delivery system, rapid deployment and movement of the delivery system by the operator.In this case, there was no allegation or indication a product deficiency malfunction contributed to this adverse event.  investigation results suggest/indicate procedural factors (valve positioning prior deployment, placement of s3 valve in a borderline size native pulmonic valve) likely contributed to the too pulmonic position of the initial sapien 3 valve and subsequent deployment of a second valve.A review of edwards lifesciences risk management documentation was performed for this case. the reported event is an anticipated risk of the transcatheter heart valve procedure, additional assessment of the failure mode is not required at this time.Complaint histories for all reported events are reviewed against trending control limits on a monthly basis, and any excursions above the control limits are assessed and documented as part of this monthly review.No corrective or preventative actions are required.
 
Event Description
As reported by an edwards affiliate in (b)(6), regarding a 26mm sapien 3 valve into a failed surgical valve, in pulmonic position by transfemoral approach.As reported, the surgical valve as very thickened and difficult to cross with the common, fairly acute angle from the rvot to the pulmonary artery.As a result, it was very difficult to position the delivery system perfectly parallel to the long axis of the prosthesis before deployment.Usually, a very slow balloon inflation allows for some adjustment of positioning and often re-orients the valve favorably before final balloon inflation.In this case, however, the sapien 3 valve position could not be adjusted as it had caught, or stuck to, the old thickening prosthesis.With the final balloon inflation, the valve did not re-orient in the prosthesis, so the ¿inside¿ of the curve delivered the s3 too distal in the prosthesis.There was no portion of the stent below the prosthetic valve ring (>100/0).The operator was not satisfied that this position was sufficiently stable/secure to leave it alone, therefore, a second valve was necessary.There was mild-moderate pvl around the sapien 3 within the surgical valve due to the high position.Second valve (a new 26mm sapien 3) was deployed without any difficulty, placing it slightly lower than ¿standard¿, to ensure complete overlap with the old prosthesis.The result was excellent.Patient discharged in stable condition. no other procedural complications were experienced.No further info is available.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE
Type of Device
PULMONARY VALVE PROSTHESIS PERCUTANEOUSLY DELIVERED
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES LLC
1 edwards way
irvine CA 92614
Manufacturer Contact
renee van dorne
1 edwards way
irvine, CA 92614
9492506385
MDR Report Key10690972
MDR Text Key211909459
Report Number2015691-2020-13995
Device Sequence Number1
Product Code NPV
Combination Product (y/n)N
Reporter Country CodeCA
PMA/PMN Number
P200015
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Remedial Action Other
Type of Report Initial
Report Date 09/23/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/16/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date03/03/2022
Device Model Number9600TFX26
Device Catalogue NumberN/A
Device Lot NumberN/A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received09/23/2020
Date Device Manufactured03/23/2020
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age26 YR
-
-